BioSpace News Archive

Genomma Lab Internacional, S.A.B. de C.V., one of the leading pharmaceutical and personal care product companies in Mexico with an expanding international presence, announces its 2025 Sustainability Strategy, underscoring the importance of sustainability in fulfilling the Company’s mandate of delivering transformational products which empower customers to thrive through optimal health and well-being.

Partner Therapeutics, Inc. (PTx), a commercial biotech company, announces a licensing and collaboration agreement with Munich-based SIRS Theraputics and Vienna-based F4 Pharma to support the development of FX-06, a synthetic peptide that has a broad spectrum of potential indications.

The International Consortium for Health Outcomes Measurement (ICHOM) signs a multi-year agreement with Dutch health analytics company LOGEX to launch the ICHOM Global Benchmarking Platform.

Geneoscopy Inc., a life sciences company that develops diagnostic tests for gastrointestinal health, today announced the appointment of Vince Wong as Chief Commercial Officer.

A new review article published in the March issue of the Journal of the American Academy of Orthopaedic Surgeons examines the variability that exists in opioid prescribing patterns across the United States for many common orthopaedic procedures.

Today, Health Canada authorized a submission from Pfizer-BioNTech to allow its COVID-19 vaccine to be stored and transported at standard freezer temperatures (between -25°C and -15°C) for up to two weeks instead of ultra-cold conditions, facilitating more flexible transportation and local re-distribution of this vaccine

As researchers around the world work to identify and address risk factors for severe COVID-19, there is additional evidence that certain blood types could be associated with greater risk of contracting the disease

Antibe Therapeutics Inc. (TSX: ATE, OTCQX: ATBPF), a clinical stage company leveraging its unique hydrogen sulfide platform to develop next-generation safer therapies to address inflammation arising from a wide range of medical conditions, today announced its participation in the following investor conferences in March: H.C. Wainwright Global Life Sciences Conference on Tuesday, March 9, 2021 at 7:00 am (Eastern Time)

Expects preliminary Phase 1/2 safety and biomarker and preliminary clinical data for TSHA-101 in GM2 gangliosidosis from the Queen’s University study in second half of 2021 and by year-end 2021, respectively Plans to initiate Phase 1/2 clinical trial for TSHA-118 in CLN1 disease in the second half of 2021 and Phase 1/2 clinical trials for TSHA-102 in Rett syndrome and TSHA-104 in SURF1-associated Leigh syndrome by year-end

InflaRx N.V. (Nasdaq: IFRX), a clinical-stage biopharmaceutical company developing anti-inflammatory therapeutics by targeting the complement system, today announced that management will present at two upcoming virtual investor conferences. H.C. Wainwright Global Life Sciences Conference March 9-10, 2021